Literature DB >> 8501331

Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect.

D L Stevens1, S Yan, A E Bryant.   

Abstract

Mechanisms to explain the "inoculum effect" have not been elucidated in gram-positive infections. A mouse model of group A streptococcal myositis was used to compare the efficacies of two beta-lactams, penicillin and ceftriaxone, and a protein synthesis inhibitor, clindamycin, at three different inoculum sizes. beta-lactams were more susceptible to inoculum effects than was clindamycin both in vivo and in vitro (P < .05). The large inocula were hypothesized to reach stationary phase of growth sooner than smaller inocula both in vitro and in vivo. The penicillin-binding protein (PBP) patterns from membrane proteins isolated from mid-log-phase and stationary-phase cultures of Streptococcus pyogenes were compared. Binding of radiolabeled penicillin by all PBPs was decreased in stationary cells; however, PBPs 1 and 4 were undetectable at 36 h. Thus, the loss of certain PBPs during stationary-phase growth in vitro may be responsible for the inoculum effect observed in vivo and may account for the failure of penicillin in both experimental and human cases of severe streptococcal infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501331     DOI: 10.1093/infdis/167.6.1401

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin.

Authors:  Susan Boyle-Vavra; Shaohui Yin; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

2.  Increasing Antimicrobial Resistance: Therapeutic Implications for Enterococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

3.  Therapeutic Approaches to Streptococcal Toxic Shock Syndrome.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

4.  Mathematical modeling to characterize the inoculum effect.

Authors:  Pratik Bhagunde; Kai-Tai Chang; Renu Singh; Vandana Singh; Kevin W Garey; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

5.  Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.

Authors:  Jürgen B Bulitta; Martina Kinzig; Verena Jakob; Ulrike Holzgrabe; Fritz Sörgel; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

6.  Growth phase-dependent effect of clindamycin on production of exoproteins by Streptococcus pyogenes.

Authors:  Jun Sawai; Tadao Hasegawa; Takuya Kamimura; Akira Okamoto; Daisuke Ohmori; Nobuyuki Nosaka; Keiko Yamada; Keizo Torii; Michio Ohta
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

Review 7.  Skin microbiota: a source of disease or defence?

Authors:  A L Cogen; V Nizet; R L Gallo
Journal:  Br J Dermatol       Date:  2008-03       Impact factor: 9.302

8.  Effects of selective and nonselective nonsteroidal anti-inflammatory drugs on antibiotic efficacy of experimental group A streptococcal myonecrosis.

Authors:  Stephanie M Hamilton; Clifford R Bayer; Dennis L Stevens; Amy E Bryant
Journal:  J Infect Dis       Date:  2013-11-11       Impact factor: 5.226

Review 9.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

10.  Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa.

Authors:  Jürgen B Bulitta; Neang S Ly; Jenny C Yang; Alan Forrest; William J Jusko; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.